Free tool
FAERS Monitor: Xphozah
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213931 or its brand name (Xphozah, Tenapanor Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
23
Serious
18
78% of reports
Hospitalization
9
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea3
- anaemia2
- asthenia2
- cough2
- covid-192
- decreased appetite2
- diarrhoea2
- drug ineffective2
- drug ineffective for unapproved indication2
- fatigue2
- gastrointestinal disorder2
- pre-existing condition improved2
- abdominal discomfort1
- abdominal pain1
- abdominal wall haematoma1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 6 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,136 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abdominal wall haematoma | 1 | 469.0 | 68.9 | 116 |
| pre-existing condition improved | 2 | 293.1 | 77.9 | 327 |
| drug ineffective for unapproved indication | 2 | 33.3 | 8.9 | 35 |
| gastrointestinal disorder | 2 | 20.4 | 5.4 | 20 |
| covid-19 | 2 | 10.4 | 2.8 | 9 |
| anaemia | 2 | 9.6 | 2.6 | 8 |
| decreased appetite | 2 | 7.9 | 2.1 | 6 |
| cough | 2 | 6.5 | 1.7 | 5 |
| abdominal discomfort | 1 | 5.5 | 0.8 | 1 |
| asthenia | 2 | 4.9 | 1.3 | 3 |
| abdominal pain | 1 | 3.9 | 0.6 | 0 |
| nausea | 3 | 3.5 | 1.2 | 3 |
| diarrhoea | 2 | 2.8 | 0.8 | 1 |
| fatigue | 2 | 2.3 | 0.6 | 1 |
| drug ineffective | 2 | 1.4 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.